MA24361A1 - Procede pouyr la preparation d'antagonistes de recepteur de vitronectine - Google Patents

Procede pouyr la preparation d'antagonistes de recepteur de vitronectine

Info

Publication number: MA24361A1
Authority: MA; Morocco
Prior art keywords: preparation; receptor antagonists; vitronectin receptor; vitronectin; antagonists
Prior art date: 1996-10-02

Application number

MA24817A

Other languages

English (en)

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-02

Filing date

1997-09-30

Publication date

1998-07-01

1997-09-30 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

1998-07-01 Publication of MA24361A1 publication Critical patent/MA24361A1/fr

Links

102100022337 Integrin alpha-V Human genes 0.000 title 1
108010048673 Vitronectin Receptors Proteins 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Inorganic Chemistry (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

MA24817A 1996-10-02 1997-09-30 Procede pouyr la preparation d'antagonistes de recepteur de vitronectine MA24361A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2732096P	1996-10-02	1996-10-02
US4377697P	1997-04-11	1997-04-11

Publications (1)

Publication Number	Publication Date
MA24361A1 true MA24361A1 (fr)	1998-07-01

Family

ID=26702318

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA24817A MA24361A1 (fr)	1996-10-02	1997-09-30	Procede pouyr la preparation d'antagonistes de recepteur de vitronectine

Country Status (36)

Country	Link
EP (1)	EP0957917B1 (fr)
JP (2)	JP4491072B2 (fr)
KR (1)	KR100589578B1 (fr)
CN (1)	CN1114403C (fr)
AP (1)	AP1463A (fr)
AR (1)	AR008878A1 (fr)
AT (1)	ATE312089T1 (fr)
AU (1)	AU733417B2 (fr)
BG (1)	BG64581B1 (fr)
BR (1)	BR9712248B1 (fr)
CA (1)	CA2267224C (fr)
CO (1)	CO4900046A1 (fr)
CY (1)	CY2576B1 (fr)
CZ (1)	CZ299076B6 (fr)
DE (1)	DE69734833T2 (fr)
DK (1)	DK0957917T3 (fr)
DZ (1)	DZ2320A1 (fr)
EA (1)	EA002419B1 (fr)
ES (1)	ES2252775T3 (fr)
HU (1)	HU229221B1 (fr)
ID (1)	ID19623A (fr)
IL (1)	IL129243A (fr)
MA (1)	MA24361A1 (fr)
MY (1)	MY137606A (fr)
NO (1)	NO320194B1 (fr)
NZ (1)	NZ334953A (fr)
PE (1)	PE10499A1 (fr)
PL (1)	PL190859B1 (fr)
RO (1)	RO119881B1 (fr)
SA (1)	SA98180936B1 (fr)
SK (1)	SK285029B6 (fr)
TR (1)	TR199900737T2 (fr)
TW (1)	TW487702B (fr)
UA (1)	UA60311C2 (fr)
UY (2)	UY24735A1 (fr)
WO (1)	WO1998014192A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA60311C2 (uk) *	1996-10-02	2003-10-15	Смітклайн Бічам Корпорейшн	Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en)	1997-07-02	2003-04-11	Bristol Myers Squibb Co	Inhibitors of farnesyl protein transferase
WO1999015178A1 (fr) *	1997-09-24	1999-04-01	Smithkline Beecham Corporation	Antagoniste du recepteur de la vitronectine
AU9577498A (en) *	1997-09-24	1999-04-12	Smithkline Beecham Corporation	Vitronectin receptor antagonist
US6372719B1 (en)	1998-03-04	2002-04-16	Jay Cunningham	ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de)	1998-09-16	2000-03-23	Merck Patent Gmbh	Pharmazeutische Zubereitung
CN1398189A (zh) *	1998-12-23	2003-02-19	G.D.西尔公司	用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
EP1150965A4 (fr) *	1999-02-03	2002-05-15	Merck & Co Inc	Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
ATE433752T1 (de) *	1999-04-30	2009-07-15	Univ Michigan	Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis
EP1208101A4 (fr) *	1999-08-06	2003-03-19	Smithkline Beecham Corp	Antagonistes du recepteur de la vitronectine utiles pour le traitement des accidents vasculaires cerebraux
US6514964B1 (en)	1999-09-27	2003-02-04	Amgen Inc.	Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10027514A1 (de) *	2000-06-06	2002-01-03	Basf Ag	Liganden von Integrinrezeptoren
DE10028575A1 (de)	2000-06-14	2002-03-14	Basf Ag	Integrinliganden
FR2806082B1 (fr) *	2000-03-07	2002-05-17	Adir	Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ539682A (en)	2001-01-29	2006-03-31	Dimensional Pharm Inc	Substituted indoles and their use as integrin antagonists
BR0208789A (pt) *	2001-04-10	2004-03-09	Smithkline Beecham Corp	Método para inibição da formação de adesão
SE0101386D0 (sv)	2001-04-20	2001-04-20	Astrazeneca Ab	New compounds
CA2445679A1 (fr) *	2001-05-03	2002-11-14	Paul J. Coleman	Benzazepinones, antagonistes de recepteur d'integrine alpha v
WO2003059251A2 (fr)	2001-10-22	2003-07-24	The Scripps Research Institute	Composes de ciblage d'anticorps
GB0215867D0 (en) *	2002-07-09	2002-08-14	Glaxosmithkline Spa	Novel method and compounds
US7368566B2 (en) *	2003-04-04	2008-05-06	Smithkline Beecham Corporation	Process and intermediates for preparing benzazepines
PL1734996T3 (pl) *	2004-04-02	2013-09-30	Univ California	Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5
AU2012216372B2 (en) *	2004-04-02	2015-01-22	The Regents Of The University Of California	Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en)	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AR052823A1 (es) *	2004-12-21	2007-04-04	Smithkline Beecham Corp	Uso de un antagonista del receptor de vitronectina para l a preparacion de una formulacion farmaceutica util para inhibir el exceso de formacion de cicatrices en la piel de a un mamifero y dicha formulacion
PL1968594T3 (pl) *	2005-11-29	2011-03-31	Glaxosmithkline Llc	Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
US9345739B2 (en)	2007-11-08	2016-05-24	The General Hospital Corporation	Methods and compositions for the treatment of proteinuric diseases
AU2008321770B2 (en) *	2007-11-16	2012-09-06	Ube Industries, Ltd.	Benzazepinone compound
US8076475B2 (en) *	2008-03-06	2011-12-13	Glaxosmithkline Llc	Process
WO2010093706A2 (fr)	2009-02-10	2010-08-19	The Scripps Research Institute	Vaccination programmée chimiquement
WO2010113958A1 (fr)	2009-03-30	2010-10-07	宇部興産株式会社	Composition pharmaceutique pour la prévention ou le traitement de maladies ophtalmiques
JP5572996B2 (ja) *	2009-05-15	2014-08-20	宇部興産株式会社	ベンズアゼピノン化合物を有効成分として含有する医薬
CA2767409C (fr)	2009-07-24	2018-10-30	The Regents Of The University Of California	Procedes et compositions destines a traiter et a prevenir des maladies associees a l'integrine ?v?5
EP2501387B1 (fr)	2009-11-17	2016-07-27	The Regents Of The University Of Michigan	1,4-benzodiazépine-2,5-diones et composés apparentés présentant des propriétés thérapeutiques
EP2325194A1 (fr) *	2009-11-24	2011-05-25	Glycotope GmbH	Processus de purification de glycoprotéines
ES2864079T3 (es)	2014-05-30	2021-10-13	Pfizer	Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
BR112022021228A2 (pt) *	2020-04-26	2022-12-06	Jiangsu Nhwa Pharmaceutical Co Ltd	Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo
WO2023275715A1 (fr)	2021-06-30	2023-01-05	Pfizer Inc.	Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG63579A1 (en) *	1992-12-21	1999-03-30	Smithkline Beecham Corp	Bicyclic fibrinogen antagonists
ZA955391B (en) *	1994-06-29	1996-02-09	Smithkline Beecham Corp	Vitronectin receptor antagonists
AU702661B2 (en) *	1994-06-29	1999-02-25	Smithkline Beecham Corporation	Vitronectin receptor antagonists
WO1996006087A1 (fr) *	1994-08-22	1996-02-29	Smithkline Beecham Corporation	Composes bicycliques
WO1996026190A1 (fr) *	1995-02-22	1996-08-29	Smithkline Beecham Corporation	Antagonistes des recepteurs a l'integrine
UA60311C2 (uk) *	1996-10-02	2003-10-15	Смітклайн Бічам Корпорейшн	Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

1997
- 1997-01-10 UA UA99031739A patent/UA60311C2/uk unknown
- 1997-09-29 DZ DZ970170A patent/DZ2320A1/fr active
- 1997-09-30 MY MYPI97004552A patent/MY137606A/en unknown
- 1997-09-30 MA MA24817A patent/MA24361A1/fr unknown
- 1997-10-01 RO RO99-00353A patent/RO119881B1/ro unknown
- 1997-10-01 AT AT97909979T patent/ATE312089T1/de active
- 1997-10-01 CO CO97057225A patent/CO4900046A1/es unknown
- 1997-10-01 DK DK97909979T patent/DK0957917T3/da active
- 1997-10-01 UY UY24735A patent/UY24735A1/es not_active IP Right Cessation
- 1997-10-01 JP JP51694298A patent/JP4491072B2/ja not_active Expired - Fee Related
- 1997-10-01 EP EP97909979A patent/EP0957917B1/fr not_active Expired - Lifetime
- 1997-10-01 ES ES97909979T patent/ES2252775T3/es not_active Expired - Lifetime
- 1997-10-01 TR TR1999/00737T patent/TR199900737T2/xx unknown
- 1997-10-01 HU HU9903769A patent/HU229221B1/hu not_active IP Right Cessation
- 1997-10-01 DE DE69734833T patent/DE69734833T2/de not_active Expired - Lifetime
- 1997-10-01 WO PCT/US1997/018001 patent/WO1998014192A1/fr not_active Ceased
- 1997-10-01 CA CA002267224A patent/CA2267224C/fr not_active Expired - Fee Related
- 1997-10-01 KR KR1019997002811A patent/KR100589578B1/ko not_active Expired - Fee Related
- 1997-10-01 IL IL12924397A patent/IL129243A/en not_active IP Right Cessation
- 1997-10-01 CN CN97180168A patent/CN1114403C/zh not_active Expired - Fee Related
- 1997-10-01 BR BRPI9712248-3A patent/BR9712248B1/pt not_active IP Right Cessation
- 1997-10-01 AP APAP/P/1999/001493A patent/AP1463A/en active
- 1997-10-01 SK SK425-99A patent/SK285029B6/sk not_active IP Right Cessation
- 1997-10-01 PL PL332674A patent/PL190859B1/pl unknown
- 1997-10-01 EA EA199900356A patent/EA002419B1/ru not_active IP Right Cessation
- 1997-10-01 PE PE1997000876A patent/PE10499A1/es not_active Application Discontinuation
- 1997-10-01 CZ CZ0113299A patent/CZ299076B6/cs not_active IP Right Cessation
- 1997-10-01 AU AU47462/97A patent/AU733417B2/en not_active Ceased
- 1997-10-01 ID IDP973335A patent/ID19623A/id unknown
- 1997-10-01 NZ NZ334953A patent/NZ334953A/xx not_active IP Right Cessation
- 1997-10-02 AR ARP970104549A patent/AR008878A1/es active IP Right Grant
1998
- 1998-02-10 TW TW086114545A patent/TW487702B/zh not_active IP Right Cessation
- 1998-03-01 SA SA98180936A patent/SA98180936B1/ar unknown
- 1998-03-25 UY UY24935A patent/UY24935A1/es not_active IP Right Cessation
1999
- 1999-03-31 BG BG103299A patent/BG64581B1/bg unknown
- 1999-03-31 NO NO19991590A patent/NO320194B1/no not_active IP Right Cessation
2007
- 2007-05-18 CY CY0700010A patent/CY2576B1/xx unknown
2009
- 2009-10-09 JP JP2009235447A patent/JP2010006838A/ja active Pending

Also Published As

Publication number	Publication date
SK42599A3 (en)	1999-12-10
KR20000048816A (ko)	2000-07-25
TW487702B (en)	2002-05-21
EP0957917A1 (fr)	1999-11-24
HK1023730A1 (en)	2000-09-22
IL129243A0 (en)	2000-02-17
JP2010006838A (ja)	2010-01-14
EA002419B1 (ru)	2002-04-25
WO1998014192A1 (fr)	1998-04-09
AU4746297A (en)	1998-04-24
DE69734833D1 (de)	2006-01-12
UY24735A1 (es)	1998-03-30
BR9712248A (pt)	1999-08-24
SA98180936B1 (ar)	2006-05-30
EA199900356A1 (ru)	2000-02-28
CA2267224C (fr)	2007-03-13
CZ113299A3 (cs)	2000-03-15
PL190859B1 (pl)	2006-02-28
JP2001501936A (ja)	2001-02-13
HU229221B1 (en)	2013-09-30
UY24935A1 (es)	2001-07-31
NO991590D0 (no)	1999-03-31
NO320194B1 (no)	2005-11-14
CY2576B1 (en)	2008-07-02
HUP9903769A2 (hu)	2000-03-28
UA60311C2 (uk)	2003-10-15
BG103299A (en)	2000-01-31
TR199900737T2 (xx)	1999-07-21
DK0957917T3 (da)	2006-04-18
NO991590L (no)	1999-05-31
CN1114403C (zh)	2003-07-16
PL332674A1 (en)	1999-09-27
EP0957917B1 (fr)	2005-12-07
JP4491072B2 (ja)	2010-06-30
EP0957917A4 (fr)	2002-05-15
RO119881B1 (ro)	2005-05-30
AP1463A (en)	2005-09-10
DE69734833T2 (de)	2006-07-13
CA2267224A1 (fr)	1998-04-09
IL129243A (en)	2004-07-25
BG64581B1 (bg)	2005-08-31
MY137606A (en)	2009-02-27
AP9901493A0 (en)	1999-03-31
DZ2320A1 (fr)	2002-12-28
ATE312089T1 (de)	2005-12-15
SK285029B6 (sk)	2006-04-06
CO4900046A1 (es)	2000-03-27
ID19623A (id)	1998-07-23
NZ334953A (en)	2000-01-28
CZ299076B6 (cs)	2008-04-16
PE10499A1 (es)	1999-03-27
BR9712248B1 (pt)	2010-06-29
AR008878A1 (es)	2000-02-23
ES2252775T3 (es)	2006-05-16
CN1238689A (zh)	1999-12-15
HUP9903769A3 (en)	2000-07-28
KR100589578B1 (ko)	2006-06-15
AU733417B2 (en)	2001-05-17

Publication	Publication Date	Title
BR9508178A (pt)	1997-11-18	Antagonistas de receptor de vitronectina
BR9612327A (pt)	1999-07-13	Antagonistas receptores de vitronectina
BR9612378A (pt)	1999-07-13	Antagonistas receptores de vitronectina
BR9612381A (pt)	1999-07-13	Antagonistas receptores vitronectina
EP1047425A4 (fr)	2009-04-22	Antagonistes du recepteur de l'integrine
DK0957917T3 (da)	2006-04-18	Vitronectinreceptorantagonister
ZA955391B (en)	1996-02-09	Vitronectin receptor antagonists
NO972016D0 (no)	1997-04-30	Indolyl-Y-reseptorantagonister
NO20016067D0 (no)	2001-12-12	Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister
EP0810994A4 (fr)	1998-05-06	Antagonistes des recepteurs de fibrinogene
ATE235467T1 (de)	2003-04-15	Antagonisten des vitronectin-rezeptors
EP0866705A4 (fr)	1999-03-03	Antagonistes du recepteur de fibrinogene
NO20004503L (no)	2000-10-10	Vitronectin-reseptor-antagonister
PL339381A1 (en)	2000-12-18	Antagonists of vitronectin receptor
IS4597A (is)	1997-10-22	Ný lyfjafræðileg notkun AII-viðtaka mótlyfja
BR9408265A (pt)	1996-12-10	Antagonistas de receptor de c5a não tendo substancialmente nenhuma atividade de antagonista
EP0781133A4 (fr)	1997-12-10	Antagonistes du recepteur de fibrinogene
FR2736635B1 (fr)	1997-08-14	Procede de preparation d'alpha,omega-bromochloroalcanes
NO20004422D0 (no)	2000-09-05	FremgangsmÕte for fremstilling av sulfanyl-type endothelinreseptor-antagonister
SI0957917T1 (sl)	2006-04-30	Antagonisti receptorja vitronektina
FR2736634B1 (fr)	1997-08-14	Procede de preparation d'alpha,omega-bromochloroalcanes